Literature DB >> 18615538

No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.

K Fall1, J R Stark, L A Mucci, J Chan, M J Stampfer, T Kurth, P G Febbo, P Kantoff, J Ma.   

Abstract

OBJECTIVE: Insulin receptor substrate-1 (IRS-1) acts as a docking protein between the insulin-like growth factor-1 (IGF-1) receptor and intracellular signaling molecules in the IGF-1 signaling pathway. Accumulating data support a role of IGF-1 in prostate carcinogenesis. We assessed the influence of the most common IRS-1 gene polymorphism (Gly972Arg) on prostate cancer risk, alone and in combination with IGF-1 and other components in the IGF-1 signaling pathway.
MATERIALS AND METHODS: In a nested case-control study within the Physicians' Health Study, the IRS-1 polymorphism was assayed from prospectively collected samples from 564 incident prostate cancer cases and 758 controls matched on age and smoking. We calculated relative risks (RR) and 95% confidence intervals (CI) using conditional logistic regression.
RESULTS: Among the controls, 0.8% were homozygous (AA) and 12% were heterozygous (GA) for the polymorphic allele. There was no association between carriage of the A allele and total prostate cancer risk (RR = 1.1 95% CI = 0.8-1.5), advanced disease (stage C or D or lethal prostate cancer, RR = 1.3 95% CI = 0.8-2.3), or plasma IGF-1 levels. We explored possible interactions with body mass index and components in the IGF-1 pathway including IGFBP3, PI3k, and PTEN but none of these factors influenced the relation between IRS-1 genotype and prostate cancer risk.
CONCLUSIONS: Our data do not support an association between carriage of the variant IRS-1 gene and prostate cancer risk. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615538      PMCID: PMC2958090          DOI: 10.1002/pros.20797

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  14 in total

1.  PTEN polymorphism (IVS4) is not associated with risk of prostate cancer.

Authors:  D J George; T F Shepard; J Ma; E Giovannucci; P W Kantoff; M J Stampfer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-04       Impact factor: 4.254

2.  Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study.

Authors:  Aimée E Paradis; Philip W Kantoff; Edward Giovannucci; Meir J Stampfer; Jing Ma
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-02       Impact factor: 4.254

3.  No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer.

Authors:  Li Li; Mine S Cicek; Graham Casey; John S Witte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-10       Impact factor: 4.254

Review 4.  The contradictions of the insulin-like growth factor 1 receptor.

Authors:  R Baserga
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

5.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

Authors:  June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci
Journal:  J Natl Cancer Inst       Date:  2002-07-17       Impact factor: 13.506

6.  Final report on the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

7.  Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer.

Authors:  Martha L Slattery; Wade Samowitz; Karen Curtin; Khe Ni Ma; Michael Hoffman; Bette Caan; Susan Neuhausen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-07       Impact factor: 4.254

8.  Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies.

Authors:  A Jellema; M P A Zeegers; E J M Feskens; P C Dagnelie; R P Mensink
Journal:  Diabetologia       Date:  2003-06-18       Impact factor: 10.122

9.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.

Authors:  C H Hennekens; J E Buring; J E Manson; M Stampfer; B Rosner; N R Cook; C Belanger; F LaMotte; J M Gaziano; P M Ridker; W Willett; R Peto
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

10.  Metabolic risk markers in an overweight and normal weight population with oversampling of carriers of the IRS-1 972Arg-variant.

Authors:  Annemarie Jellema; Ronald P Mensink; Daan Kromhout; Wim H M Saris; Edith J M Feskens
Journal:  Atherosclerosis       Date:  2003-11       Impact factor: 5.162

View more
  6 in total

1.  Association of IRS1 Gly972Arg and IRS2 Gly1057Asp polymorphisms with gastric cancer in Turkish subjects.

Authors:  Gokhan Gorgisen; Ugur Karatas; Can Ates; Murat Oksuz; Ismail Musab Gulacar
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

2.  Genetic variation in RNASEL associated with prostate cancer risk and progression.

Authors:  Mara S Meyer; Kathryn L Penney; Jennifer R Stark; Fredrick R Schumacher; Howard D Sesso; Massimo Loda; Michelangelo Fiorentino; Stephen Finn; Richard J Flavin; Tobias Kurth; Alkes L Price; Edward L Giovannucci; Katja Fall; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2010-06-24       Impact factor: 4.944

3.  Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk.

Authors:  Hongtuan Zhang; Andi Wang; Hui Ma; Yong Xu
Journal:  Tumour Biol       Date:  2013-05-25

4.  The Role of Polymorphisms in Genes of PI3K/Akt Signaling Pathway on Prostate.

Authors:  Wei Xu; Zhihao Ni; Meng Zhang; Jinbo Chen; Li Zhang; Song Wu; Chaozhao Liang
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

Review 5.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

6.  Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction.

Authors:  Ricardo J T Ribeiro; Cátia P D Monteiro; Andreia S M Azevedo; Virgínia F M Cunha; Agnihotram V Ramanakumar; Avelino M Fraga; Francisco M Pina; Carlos M S Lopes; Rui M Medeiros; Eduardo L Franco
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.